Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
September 2011

Vilazodone (Viibryd) Part II
Evidence to date shows no significant benefit of the new selective serotonin reuptake inhibitor (SSRI) vilazodone (Viibryd) over other antidepressants.

Remember Clozapine
Clozapine (Clozaril and others) carries a wide range of side effects, but it is still the most efficacious antipsychotic when patients are inadequately responsive to other agents.

In Brief
New Cardiac Warning Added to Labeling for Quetiapine (Seroquel); Atomoxetine (Strattera) Does Not Attenuate Weight Gain in Patients with Schizophrenia

No Help from the "Sunshine Vitamin"
In a nonclinical elderly population, vitamin D supplementation had no significant effect on mood or other mental health outcomes.

Vilazodone (Viibryd) Part II

September 2011

In March, we summarized available information on the recently introduced antidepressant vilazodone (Viibryd) (BTP 2011;34:9). A selective serotonin reuptake inhibitor (SSRI) and partial 5-HT1A agonist, vilazodone is being promoted with the suggestion that it will treat depression faster…

To view the rest of this article, please: